Az elorehaladott Hodgkin-kór elsodleges kezelése

Translated title of the contribution: Primary treatment of advanced Hodgkin's disease

A. Illés, M. Udvardy, Zsuzsa Molnár

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hodgkin's disease is one of the few malignant diseases that can be cured even in an advanced stage in the majority of cases. By employing a polychemotherapy containing anthracyclin, a long remission and recovery can be achieved in 60-70% of the patients. At present the standard treatment is ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) scheme for the following reasons: besides good treatment results early side effects are more favourable; sterility and secondary acute leukemia present themselves less often than by employing regimens containing alkylating agents. Unfortunately, some of the patients do not react properly to the treatment and about one third of the patients who are in remission following primary treatment will relapse at a later stage. The main goal is now to further improve treatment (recovery) results without an increase, or even a decrease of early or late side effects. Awareness of prognostic factors should lead to the employment of a less intensive but not toxic therapy in patients with good prognosis to prevent overtreatment, while in cases with bad prognosis a more effective regimen is needed (even for the price of expected complications). The latest metaanalysis on the subject has shown that - similarly to sequential high dose therapy - the addition of radiotherapy to an effective chemotherapy does not seem to prolong the survival of patients. Despite the excellent therapeutic results achieved by the many new "intensive" chemotherapies, there is unfortunately no optimal therapy or protocol available today. The multicentre analysis to confirm these results and to compare them with standard scheme is still under way. It is to be hoped that risk adapted management for advanced stage Hodgkin's disease will also be available soon.

Original languageHungarian
Pages (from-to)195-202
Number of pages8
JournalOrvosi Hetilap
Volume146
Issue number5
Publication statusPublished - 2005

Fingerprint

Hodgkin Disease
Therapeutics
Drug Therapy
Dacarbazine
Vinblastine
Poisons
Alkylating Agents
Bleomycin
Risk Management
Combination Drug Therapy
Doxorubicin
Infertility
Leukemia
Radiotherapy
Recurrence
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az elorehaladott Hodgkin-kór elsodleges kezelése. / Illés, A.; Udvardy, M.; Molnár, Zsuzsa.

In: Orvosi Hetilap, Vol. 146, No. 5, 2005, p. 195-202.

Research output: Contribution to journalArticle

Illés, A. ; Udvardy, M. ; Molnár, Zsuzsa. / Az elorehaladott Hodgkin-kór elsodleges kezelése. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 5. pp. 195-202.
@article{4d18e6cefe1f4bd78dbe246d21d35cdc,
title = "Az elorehaladott Hodgkin-k{\'o}r elsodleges kezel{\'e}se",
abstract = "Hodgkin's disease is one of the few malignant diseases that can be cured even in an advanced stage in the majority of cases. By employing a polychemotherapy containing anthracyclin, a long remission and recovery can be achieved in 60-70{\%} of the patients. At present the standard treatment is ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) scheme for the following reasons: besides good treatment results early side effects are more favourable; sterility and secondary acute leukemia present themselves less often than by employing regimens containing alkylating agents. Unfortunately, some of the patients do not react properly to the treatment and about one third of the patients who are in remission following primary treatment will relapse at a later stage. The main goal is now to further improve treatment (recovery) results without an increase, or even a decrease of early or late side effects. Awareness of prognostic factors should lead to the employment of a less intensive but not toxic therapy in patients with good prognosis to prevent overtreatment, while in cases with bad prognosis a more effective regimen is needed (even for the price of expected complications). The latest metaanalysis on the subject has shown that - similarly to sequential high dose therapy - the addition of radiotherapy to an effective chemotherapy does not seem to prolong the survival of patients. Despite the excellent therapeutic results achieved by the many new {"}intensive{"} chemotherapies, there is unfortunately no optimal therapy or protocol available today. The multicentre analysis to confirm these results and to compare them with standard scheme is still under way. It is to be hoped that risk adapted management for advanced stage Hodgkin's disease will also be available soon.",
keywords = "Advanced stage, Chemotherapy, Hodgkin's disease, Prognostic factors, Radiotherapy, Treatment",
author = "A. Ill{\'e}s and M. Udvardy and Zsuzsa Moln{\'a}r",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "195--202",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "5",

}

TY - JOUR

T1 - Az elorehaladott Hodgkin-kór elsodleges kezelése

AU - Illés, A.

AU - Udvardy, M.

AU - Molnár, Zsuzsa

PY - 2005

Y1 - 2005

N2 - Hodgkin's disease is one of the few malignant diseases that can be cured even in an advanced stage in the majority of cases. By employing a polychemotherapy containing anthracyclin, a long remission and recovery can be achieved in 60-70% of the patients. At present the standard treatment is ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) scheme for the following reasons: besides good treatment results early side effects are more favourable; sterility and secondary acute leukemia present themselves less often than by employing regimens containing alkylating agents. Unfortunately, some of the patients do not react properly to the treatment and about one third of the patients who are in remission following primary treatment will relapse at a later stage. The main goal is now to further improve treatment (recovery) results without an increase, or even a decrease of early or late side effects. Awareness of prognostic factors should lead to the employment of a less intensive but not toxic therapy in patients with good prognosis to prevent overtreatment, while in cases with bad prognosis a more effective regimen is needed (even for the price of expected complications). The latest metaanalysis on the subject has shown that - similarly to sequential high dose therapy - the addition of radiotherapy to an effective chemotherapy does not seem to prolong the survival of patients. Despite the excellent therapeutic results achieved by the many new "intensive" chemotherapies, there is unfortunately no optimal therapy or protocol available today. The multicentre analysis to confirm these results and to compare them with standard scheme is still under way. It is to be hoped that risk adapted management for advanced stage Hodgkin's disease will also be available soon.

AB - Hodgkin's disease is one of the few malignant diseases that can be cured even in an advanced stage in the majority of cases. By employing a polychemotherapy containing anthracyclin, a long remission and recovery can be achieved in 60-70% of the patients. At present the standard treatment is ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) scheme for the following reasons: besides good treatment results early side effects are more favourable; sterility and secondary acute leukemia present themselves less often than by employing regimens containing alkylating agents. Unfortunately, some of the patients do not react properly to the treatment and about one third of the patients who are in remission following primary treatment will relapse at a later stage. The main goal is now to further improve treatment (recovery) results without an increase, or even a decrease of early or late side effects. Awareness of prognostic factors should lead to the employment of a less intensive but not toxic therapy in patients with good prognosis to prevent overtreatment, while in cases with bad prognosis a more effective regimen is needed (even for the price of expected complications). The latest metaanalysis on the subject has shown that - similarly to sequential high dose therapy - the addition of radiotherapy to an effective chemotherapy does not seem to prolong the survival of patients. Despite the excellent therapeutic results achieved by the many new "intensive" chemotherapies, there is unfortunately no optimal therapy or protocol available today. The multicentre analysis to confirm these results and to compare them with standard scheme is still under way. It is to be hoped that risk adapted management for advanced stage Hodgkin's disease will also be available soon.

KW - Advanced stage

KW - Chemotherapy

KW - Hodgkin's disease

KW - Prognostic factors

KW - Radiotherapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=15744367306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15744367306&partnerID=8YFLogxK

M3 - Article

C2 - 15773586

AN - SCOPUS:15744367306

VL - 146

SP - 195

EP - 202

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 5

ER -